KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.
Rivero-Juarez A, Gonzalez R, Frias M, Manzanares-Martín B, Rodriguez-Cano D, Perez-Camacho I, Gordon A, Cuenca F, Camacho A, Pineda JA, Peña J, Rivero A.
Rivero-Juarez A, et al. Among authors: frias m.
Pharmacogenomics J. 2017 Jul;17(4):360-365. doi: 10.1038/tpj.2016.19. Epub 2016 Mar 15.
Pharmacogenomics J. 2017.
PMID: 26975229